Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 2.2%.
The iShares Biotechnology ETF (IBB) shed 1.8%.
In corporate news, Novartis (NVS) shares fell past 13% after it said a phase 3 trial assessing delpacibart etedesiran in people with myotonic dystrophy type 1 failed to meet its primary endpoint.